Tumor Biology

, Volume 35, Issue 4, pp 3803–3808 | Cite as

Strong claudin 5 expression is a poor prognostic sign in pancreatic adenocarcinoma

  • Ylermi Soini
  • M. Eskelinen
  • P. Juvonen
  • V. Kärjä
  • K. M. Haapasaari
  • A. Saarela
  • P. Karihtala
Research Article

Abstract

We investigated the expression of claudin 5 in 88 ductal adenocarcinomas of the pancreas. The results were correlated with patient prognosis, with claudin 5 expression in blood vessels, with the expression level of bcl2 and bax and with apoptosis. Claudin 5 expression was detected in 24 (38 %) cases. It was not associated with tumour size or spread, but strong claudin 5 expression correlated with a worse survival (p = 0.005). Claudin 5 also associated with a higher extent of apoptosis and greater expression of bax protein. In the tumour vasculature, some vessels displayed a loss of claudin 5 expression. The presence of this loss was associated with tumour grade and the presence of nodal metastases (p = 0.02, p = 0.022, respectively). These results indicate that claudin 5 is upregulated in a proportion of pancreatic ductal adenocarcinomas. The association of strong claudin 5 expression with a worse survival is in line with some earlier reports indicating that this protein is involved with increased locomotion and more aggressive spread of carcinomas. The association of claudin 5 with apoptosis and bax might be due to stronger cellular kinetics found in such tumours. The loss of claudin 5 expression in the tumour vasculature points to a leaky vessel type; this might also ease the access of tumours to vessels and be reflected in its association with the presence of nodal metastases.

Keywords

Pancreas Carcinoma Claudin Apoptosis 

Notes

Acknowledgments

We appreciate the support of the Finnish Anti-Tuberculosis Association and the Finnish Cancer Society.

Conflicts of interest

None

References

  1. 1.
    Krause G, Winkler L, Mueller SL, Haseloff RF, Piontek J, Blasig IE. Structure and function of claudins. Biochim Biophys Acta. 2008;1778:631–45.PubMedCrossRefGoogle Scholar
  2. 2.
    Sawada N, Murata M, Kikuchi K, Osanai M, Tobioka H, Kojima T, et al. Tight junctions and human diseases. Med Electron Microsc. 2003;36:147–56.PubMedCrossRefGoogle Scholar
  3. 3.
    Mineta K, Yamamoto Y, Yamazaki Y, Tanaka H, Tada Y, Saito K, et al. Predicted expansion of the claudin multigene family. FEBS Lett. 2011;585:606–12.PubMedCrossRefGoogle Scholar
  4. 4.
    Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wölk B, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature. 2007;446:801–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Morita K, Sasaki H, Furuse M, Tsukita S. Endothelial claudin: claudin-5/TMVCF constitutes tight junction strands in endothelial cells. J Cell Biol. 1999;147:185–94.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Morrow CM, Tyagi G, Simon L, Carnes K, Murphy KM, Cooke PS, et al. Claudin 5 expression in mouse seminiferous epithelium is dependent upon the transcription factor ets variant 5 and contributes to blood-testis barrier function. Biol Reprod. 2009;81:871–9.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, et al. Size-selective loosening of the blood–brain barrier in claudin-5-deficient mice. J Cell Biol. 2003;161:653–60.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Soini Y. Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumours. Histopathology. 2005;46:551–60.PubMedCrossRefGoogle Scholar
  9. 9.
    Turunen M, Talvensaari-Mattila A, Soini Y, Santala M. Claudin-5 overexpression correlates with aggressive behavior in serous ovarian adenocarcinoma. Anticancer Res. 2009;29:5185–9.PubMedGoogle Scholar
  10. 10.
    Escudero-Esparza A, Jiang WG, Martin TA. Claudin-5 is involved in breast cancer cell motility through the N-WASP and ROCK signalling pathways. J Exp Clin Cancer Res. 2012;31:43.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Rahner C, Mitic LL, Anderson JM. Heterogeneity in expression and subcellular localization of claudins 2, 3, 4, and 5 in the rat liver, pancreas, and gut. Gastroenterology. 2001;120:411–22.PubMedCrossRefGoogle Scholar
  12. 12.
    Comper F, Antonello D, Beghelli S, Gobbo S, Montagna L, Pederzoli P, et al. Expression pattern of claudins 5 and 7 distinguishes solid-pseudopapillary from pancreatoblastoma, acinar cell and endocrine tumors of the pancreas. Am J Surg Pathol. 2009;33:768–74.PubMedCrossRefGoogle Scholar
  13. 13.
    Karanjawala ZE, Illei PB, Ashfaq R, Infante JR, Murphy K, Pandey A, et al. New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8. Am J Surg Pathol. 2008;32:188–96.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Tsukahara M, Nagai H, Kamiakito T, Kawata H, Takayashiki N, Saito K, et al. Distinct expression patterns of claudin-1 and claudin-4 in intraductal papillary-mucinous tumors of the pancreas. Pathol Int. 2005;55:63–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. Lyon: IARC; 2009.Google Scholar
  16. 16.
    Szasz AM, Tokes AM, Micsinai M, Krenacs T, Jakab C, Lukacs L, et al. Prognostic significance of claudin expression changes in breast cancer with regional lymph node metastasis. Clin Exp Metastasis. 2011;28:55–63.PubMedCrossRefGoogle Scholar
  17. 17.
    Korompay A, Borka K, Lotz G, Somorácz A, Törzsök P, Erdélyi-Belle B, et al. Tricellulin expression in normal and neoplastic human pancreas. Histopathology. 2012;60:E76–86.PubMedCrossRefGoogle Scholar
  18. 18.
    Liu T, Sun B, Zhao X, Gu Q, Dong X, Yao Z, et al. HER2/neu expression correlates with vasculogenic mimicry in invasive breast carcinoma. J Cell Mol Med. 2013;17:116–22.PubMedCrossRefGoogle Scholar
  19. 19.
    Taddei A, Giampietro C, Conti A, Orsenigo F, Breviario F, Pirazzoli V, et al. Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5. Nat Cell Biol. 2008;10:923–34.PubMedCrossRefGoogle Scholar
  20. 20.
    Ping YF, Bian XW. Concise review: contribution of cancer stem cells to neovascularization. Stem Cells. 2011;29:888–94.PubMedCrossRefGoogle Scholar
  21. 21.
    Jouppila-Mättö A, Närkiö-Mäkelä M, Soini Y, Pukkila M, Sironen R, Tuhkanen H, et al. Twist and snai1 expression in pharyngeal squamous cell carcinoma stroma is related to cancer progression. BMC Cancer. 2011;11:350.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Kokudo T, Suzuki Y, Yoshimatsu Y, Yamazaki T, Watabe T, Miyazono K. Snail is required for TGF beta-induced endothelial-mesenchymal transition of embryonic stem cell-derived endothelial cells. J Cell Sci. 2008;121:3317–24.PubMedCrossRefGoogle Scholar
  23. 23.
    Soini Y, Tommola S, Helin H, Martikainen P. Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype. Virchows Arch. 2006;448:52–8.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Ylermi Soini
    • 1
    • 6
  • M. Eskelinen
    • 2
  • P. Juvonen
    • 2
  • V. Kärjä
    • 1
  • K. M. Haapasaari
    • 3
  • A. Saarela
    • 4
  • P. Karihtala
    • 5
  1. 1.Department of Pathology and Forensic Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, School of MedicineUniversity of Eastern Finland, Cancer Center of Eastern FinlandKuopioFinland
  2. 2.Department of Gastrointestinal Surgery, Kuopio University Hospital and School of MedicineUniversity of Eastern FinlandKuopioFinland
  3. 3.Department of PathologyUniversity of OuluOuluFinland
  4. 4.Department of Gastrointestinal SurgeryOulu University HospitalOuluFinland
  5. 5.Department of Oncology and RadiotherapyUniversity of Oulu and Oulu University HospitalOuluFinland
  6. 6.Department of Pathology and Forensic Medicine, School of MedicineUniversity of Eastern FinlandKuopioFinland

Personalised recommendations